# Joseph O. Moore

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joseph-o-moore/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,445 |
| Field | Chronic Lymphocytic Leukemia Research |
| h-index | 54 |
| i10-index | 119 |
| Last Known Institution | Johns Hopkins University |
| OpenAlex ID | https://openalex.org/A5109247403 |
| Works | 234 |

## Researcher papers

- [Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia](https://scholariq.org/papers/intensive-postremission-chemotherapy-in-adults-with-acute-myeloid-leukemia/)
- [Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/acute-myeloid-leukemia-version-3-2017-nccn-clinical-practice-guidelines-in/)
- [Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia](https://scholariq.org/papers/granulocyte-macrophage-colony-stimulating-factor-after-initial-chemotherapy-for/)
- [Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered](https://scholariq.org/papers/patients-with-t-8-21-q22-q22-and-acute-myeloid-leukemia-have-superior-failure/)
- [A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-recombinant-human-interleukin-11-in/)
- [Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia](https://scholariq.org/papers/randomized-phase-iii-trial-of-fludarabine-plus-cyclophosphamide-with-or-without/)
- [Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/chronic-myeloid-leukemia-version-1-2019-nccn-clinical-practice-guidelines-in/)
- [Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/chronic-myeloid-leukemia-version-2-2021-nccn-clinical-practice-guidelines-in/)
- [Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia](https://scholariq.org/papers/phase-iii-randomized-multicenter-study-of-a-humanized-anti-cd33-monoclonal/)
- [Expression and prognostic impact of lncRNAs in acute myeloid leukemia](https://scholariq.org/papers/expression-and-prognostic-impact-of-lncrnas-in-acute-myeloid-leukemia/)
- [Predictors of outcome of tricuspid valve replacement in carcinoid heart disease](https://scholariq.org/papers/predictors-of-outcome-of-tricuspid-valve-replacement-in-carcinoid-heart-disease/)

## Researcher topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)

## Researcher university

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.